Drugs / MEDI8367
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04365218 | Jul 2020 → Jan 2021 | chronic kidney disease | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI8367 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04365218 ↗ |
| Route | Subcutaneous | “Subjects will receive subcutaneous (SC) single dose of MEDI8367” NCT04365218 ↗ |